Anacor Pharmaceuticals Is Not for Everyone

NEW YORK (TheStreet) -- I have been talking about, writing about and, most important, investing in stocks for my clients and myself for a long time. You do not have to be a scientist or doctor to invest in scientific or medical progress.

Of the nearly 3,800 stocks I cover in my database, most do not get white-hot overnight. Neither do they lose all their value overnight.

So I look for industries first, then companies within those industries when I am selecting investments. I use the database that I created to select the Best Stocks Now.

That is how I found Anacor Pharmaceuticals (ANAC).

Data from Best Stocks Now App

I didn't hear about ANAC from a televised talking head. Nor did I read about it in the Wall Street Journal or Barron's. I found it while scouring the database that I created.

ANAC is in the atopic dermatitis business. Eczema. One of its products is getting some good results and some even say it could be a new standard of treatment for this disease. But just because something is a good company in a good industry with a good even great product, it does not necessarily mean it is a good stock.

ANAC became public in 2010 at $5 per share. I noticed it three months ago when it hit #23 based on my proprietary grading system. Looking at the chart, we see it has done a powerful saucer pattern from April until Mid-August of this year when ANAC broke out and rose up the ranks in my database.

If you liked this article you might like

Lack of Catalysts Keeps Analysts Away From Pfizer

Read Scraps Pfizer Break-Up as Megadeals Escape Its Grasp

Allergan's Dealmaking Continues With Vitae Takeout

Will Pfizer Book Another Healthy Quarter?

Ardelyx Has Big Potential

Ardelyx Has Big Potential